Abstract 13508: Elevated Plasma miR-92a as a Potential Risk Stratification Biomarker in Patients with Chronic Coronary Syndrome: A 2-Year Follow-Up Study
Abstract
Introduction: MicroRNAs are emerging biomarkers involved in the regulation of endothelial function andatherosclerotic plaque progression. MicroRNA-92a (miR-92a) downregulates Kruppel-likefactor 2 (KLF2), a key mediator of endothelial homeostasis and atheroprotection.Although elevated miR-92a expression has been linked to atherosclerotic disease, itsprognostic significance in Chronic Coronary Syndrome (CCS) remains unclear. Thepresent study evaluated the prognostic and risk-stratification value of baseline plasmamiR-92a expression in patients with angiographically confirmed CCS. Methods: Fifty-six patients with angiographically confirmed coronary artery disease and no historyof myocardial infarction were prospectively enrolled. Baseline plasma expression levels ofmiR-92a, miR-10b, miR-126, miR-98 and miR-29b were measured using RT-qPCR withspike-in normalization. Patients were followed up with after 24 months. Adversecardiovascular events were defined as death due to cardiovascular reason, myocardialinfarction, stroke, or unplanned cardiovascular hospitalization. Follow-up data wereobtained through structured telephone interviews and review of local hospital database(CliniNet). Receiver operating characteristic (ROC) analysis was performed to determinethe optimal miR-92a threshold for event discrimination. Results: Adverse cardiovascular events occurred in 15 of 56 patients (26.8%) during the 24-monthfollow-up period. Patients experiencing events demonstrated significantly higher baselinemiR-92a expression compared with event-free patients (102.96 [67.67-150.75] vs. 67.04[40.67-87.40]; p=0.017). No significant associations were observed for other investigatedmicroRNAs (miR-10b, miR-126, miR-98, or miR-29b). ROC analysis identified a miR-92athreshold of 91.92 for prediction of adverse cardiovascular events (AUC=0.706, sensitivity66.7%, specificity 75.0%). To assess clinical risk stratification, biomarker data werecombined with left ventricular ejection fraction (LVEF). The presence of either elevatedmiR-92a (>91.92) or reduced LVEF (<50%) was associated with substantially increasedodds of adverse cardiovascular events during follow-up (OR=14.0, 95% CI 2.75-71.28,p=0.0005). Conclusions: Elevated baseline miR-92a expression is associated with adverse cardiovascularoutcomes in patients with CCS. A miR-92a threshold of 91.92 demonstrated moderatediscriminatory performance, while the combination of elevated miR-92a or reduced LVEFidentified a subgroup at markedly increased risk of adverse cardiovascular events. Thesefindings suggest that circulating miR-92a may provide incremental prognostic informationbeyond established clinical parameters and warrant further investigation as a biomarkerfor cardiovascular risk stratification in chronic coronary syndrome.